Calcium channel blockers
A class of medicines that work by blocking calcium from moving into cells. The US label read for one calcium channel blocker says it may be used alone or with other blood pressure and angina medicines. It lists high blood pressure, and coronary artery disease in the forms chronic stable angina, vasospastic angina and angiographically documented disease in people without heart failure or an ejection fraction under 40%.
Also called Calcium channel blocker · Calcium antagonists
- Drug
- In this atlas
Overview
Technical summary
Class page. MeSH descriptor D002121 (Calcium Channel Blockers, last updated 2020-05-27) is an exact match, and its scope note gives the class description. The label read is the US prescribing label of one brand-name amlodipine besylate tablet (application NDA019787, effective 2023-02-15 in openFDA). The label describes amlodipine as a dihydropyridine calcium antagonist, so it does not stand for every member of the class. The label text read states no age range for its uses. This page gives no dose, no trial result and no guideline statement, and none of the label's warnings or interactions was recorded. Medicines of the class that have their own pages are filed under it.
Trials at a glance
The figures count the 11 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 11
- Phase 3 or 4
- 10
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Not yet recruiting | Completed | Suspended | Unknown status | All statuses |
|---|---|---|---|---|---|---|
| Phase 2 | 0 | 0 | 1 | 0 | 0 | 1 |
| Phase 3 | 0 | 1 | 2 | 0 | 0 | 3 |
| Phase 4 | 1 | 0 | 4 | 1 | 1 | 7 |
| All phases | 1 | 1 | 7 | 1 | 1 | 11 |
Conditions these trials study
- Hypertension (high blood pressure)
- Angina pectoris
- Arrhythmia (heart rhythm problems)
- Atrial fibrillation (AF)
- Atrial flutter
- Coronary artery disease
Sponsors with the most trials
Drugs in this class
4 drugs in this atlas are filed under Calcium channel blockers, with the registry trials and FDA regulatory decisions this atlas holds for each. With Calcium channel blockers itself, the class has 60 distinct trials and 64 distinct FDA decisions; a trial or decision that two of them share counts once there.
About this drug
- Level
- Class
- Mechanism
- MeSH says these drugs act by selective inhibition of calcium influx through cellular membranes. A US label says the one it describes inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle.
Claims and evidence
Context People with hypertension or coronary artery disease, as described in the US label of a calcium channel blocker
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label: patients with hypertension, and patients with chronic stable angina, vasospastic angina, or angiographically documented coronary artery disease without heart failure or an ejection fraction under 40%.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (US drug label)
- Life stage
- Not stated in the passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 4 inclusion criteria; exclusion criteria not stated
- Included
- Hypertension
- Chronic stable angina
- Vasospastic angina
- Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction under 40%
- Excluded
- None stated
The US label of NORVASC (amlodipine besylate tablets, Viatris Specialty LLC, application NDA019787; the version dated 2023-02-15 in openFDA) calls the medicine a calcium channel blocker that may be used on its own or in combination with other antihypertensive and antianginal agents. It lists the treatment of hypertension, and coronary artery disease in three forms: chronic stable angina, vasospastic angina, and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction under 40%. MeSH describes the class as drugs that act by selective inhibition of calcium influx through cellular membranes.
Applies to Recipient not specified People with hypertension or coronary artery disease, as described in the US label of a calcium channel blocker
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The medicine is a dihydropyridine, so the label does not stand for every calcium channel blocker. The label text read states no age range. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentences that call the medicine a calcium channel blocker and list hypertension and coronary artery disease.
- Retrieved
- Source effective date
- 2023-02-15
- Source state
- Current
- Version fingerprint
bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20230215.
- Retrieved
- Source effective date
- 2023-02-15
- Source state
- Current
- Version fingerprint
bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports MeSH scope note for descriptor D002121 (Calcium Channel Blockers)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note: what the class does.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
afa580433e9343662dc0028eebedb5b1943e77b266b29033c5597b5175cd8379- Reuse basis
- The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-10-30 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact A US label lists treating high blood pressure as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified People with hypertension or coronary artery disease, as described in the US label of a calcium channel blocker
The US label of NORVASC (amlodipine besylate tablets, Viatris Specialty LLC, application NDA019787; the version dated 2023-02-15 in openFDA) calls the medicine a calcium channel blocker that may be used on its own or in combination with other antihypertensive and antianginal agents. It lists the treatment of hypertension, and coronary artery disease in three forms: chronic stable angina, vasospastic angina, and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction under 40%. MeSH describes the class as drugs that act by selective inhibition of calcium influx through cellular membranes.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The medicine is a dihydropyridine, so the label does not stand for every calcium channel blocker. The label text read states no age range. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact A US label lists coronary artery disease as an indication: Coronary artery disease
Applies to Recipient not specified People with hypertension or coronary artery disease, as described in the US label of a calcium channel blocker
The US label of NORVASC (amlodipine besylate tablets, Viatris Specialty LLC, application NDA019787; the version dated 2023-02-15 in openFDA) calls the medicine a calcium channel blocker that may be used on its own or in combination with other antihypertensive and antianginal agents. It lists the treatment of hypertension, and coronary artery disease in three forms: chronic stable angina, vasospastic angina, and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction under 40%. MeSH describes the class as drugs that act by selective inhibition of calcium influx through cellular membranes.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The medicine is a dihydropyridine, so the label does not stand for every calcium channel blocker. The label text read states no age range. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact A US label lists chronic stable angina as an indication: Stable angina
Applies to Recipient not specified People with hypertension or coronary artery disease, as described in the US label of a calcium channel blocker
The US label of NORVASC (amlodipine besylate tablets, Viatris Specialty LLC, application NDA019787; the version dated 2023-02-15 in openFDA) calls the medicine a calcium channel blocker that may be used on its own or in combination with other antihypertensive and antianginal agents. It lists the treatment of hypertension, and coronary artery disease in three forms: chronic stable angina, vasospastic angina, and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction under 40%. MeSH describes the class as drugs that act by selective inhibition of calcium influx through cellular membranes.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The medicine is a dihydropyridine, so the label does not stand for every calcium channel blocker. The label text read states no age range. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 11
Record details
- Record id
cardio:calcium-channel-blockers- Content hash
38fb7af65e3e3a53a1e86e71ecc6efa6ab3eed1f5c4b7cf4d61b0000cabf9f16